Champion River Ventures Ltd
Known title: DirectorCIK: 0001705321
Associated companies
Transaction History
| NAGE | ▲ Buy | Open Market | 3,467,778 | — | 9/6/2023 | View on chart |
| NAGE | ▲ Buy | Open Market | 3,467,778 | — | 9/6/2023 | View on chart |
We use analytics to understand how market-wall is used. No personal data is sold.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
NAGE linked to new preclinical study on CD38 and NAD+ decline
A new preclinical study identified CD38 as a driver of age‑related NAD+ decline and showed that nicotinamide riboside can improve pregnancy outcomes in animal models. The research also reported lower NAD+ levels in placental tissue from older mothers. Niagen Bioscience clarified that it did not conduct, fund, or design the study and that the NR used was not its proprietary Niagen ingredient. The findings relate to the company’s focus on NAD+‑boosting products and may draw attention to its pipeline.
NAGE linked to new preclinical study on CD38 and NAD+ decline. A new preclinical study identified CD38 as a driver of age‑related NAD+ decline and showed that nicotinamide riboside can improve pregnancy outcomes in animal models. The research also reported lower NAD+ levels in placental tissue from older mothers. Niagen Bioscience clarified that it did not conduct, fund, or design the study and that the NR used was not its proprietary Niagen ingredient. The findings relate to the company’s focus on NAD+‑boosting products and may draw attention to its pipeline.